The DVD Trial. Source Reinecke H, Fobker M, Wellmann J, et al. A randomized controlled trial comparing hydration therapy to additional hemodialysis or.

Slides:



Advertisements
Similar presentations
Prevention of Contrast-Induced Nephropathy (CIN) Sepehr Khashaei, MD Assistant professor Department of Internal Medicine.
Advertisements

A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.
The FREEDOM Study (Impact of Short Daily Hemodialysis on Restless Legs Symptoms and Sleep Disturbances) Source Jaber BL, Schiller B, Burkart JM, et al.
Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
Renal Protection for Coronary Angiography in Advanced Renal Failure Patients by Prophylactic Hemodialysis Presented by Mike Touchy, HO-I.
REMEDIAL II Renal Insufficiency Following Contrast Media Administration Trial II (REMEDIAL II): RenalGuard™ System In High-Risk Patients for Contrast-Induced.
 Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease:
CM A pooled safety & efficacy analysis examining the effect of performance status on outcomes in 9 first line treatment trials of 6,286 patients.
3. The ASCERTAIN Study. Source Holdaas H, Rostaing L, Serón D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor.
The mortality associated with body size and muscle mass, fat mass and abdominal obesity in patients receiving hemodialysis Date: 2012/12/21 實習生:余萍 指導老師:蕭佩珍營養師.
Impact of Preoperative Renal Dysfunction in Patients Undergoing Off- pump vs On-pump Coronary Artery Bypass.
Clinical Trial Results. org Tilman B. Drüeke, M.D.; Francesco Locatelli, M.D.; Naomi Clyne, M.D.; Kai-Uwe Eckardt, M.D.; Iain C. Macdougall, M.D.; Dimitrios.
The long-term outcome after acute renal failure Presented by Ri 顏玎安.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September-October 2007.
Can we prevent myocardial and renal revascularization injury? Preventive effect of trimetazidine MR on myocardial and renal injury in diabetic patients.
Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.
NKF-KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease UPDATE OF HEMOGLOBIN TARGET Am.J.Kidney.Dis.
Proteinuria as a Surrogate Outcome in IgA Nephropathy Ron Hogg MD Scott & White Medical Center Temple, Texas.
Hemoglobin A 1c in Hemodialysis Patients Source: Ix JH. Hemoglobin A1c in hemodialysis patients: Should one size fit all? Clin J Am Soc Nephrol. 2010;5:1539–1541.
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.
Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.
LONG-TERM OUTCOME OF INTERFERON/RIBAVIRIN TREATMENT IN GERMAN REAL-LIFE SETTING: DURABLE SVR ASSOCIATED WITH LOW RATES OF LIVER-RELATED EVENTS S. Mauss.
FRAMING RESEARCH QUESTIONS The PICO Strategy. PICO P: Population of interest I: Intervention C: Control O: Outcome.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
CLAIMS STRUCTURE FOR SLE Jeffrey Siegel, M.D. Arthritis Advisory Committee September 29, 2003.
Monthly Journal article review: Vimmi Kang PGY 2
Dose Interruption/Reduction of Tyrosine Kinase Inhibitors in the First 3 Months of Treatment of CML Is Associated with Inferior Early Molecular Responses.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.
Conclusions. Conclusions -In patients undergoing primary angioplasty, prophylactic treatment with N-acetylcysteine seems to reduce the rate of contrast-medium.
Predicting Progression in Diabetic Nephropathy: New Biomarker: sTNFR1* Circulating soluble Tumor Necrosis Factor Receptor 1.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
بسم الله الرحمن الرحیم.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Short- and Long-Term Mortality After Myocardial Infarction in Patients With and Without Diabetes Featured Article: Sjoerd T. Nauta, M.S.C., Jaap W. Deckers,
High Coronary Calcification Scores Predict Mortality in Pre-Dialysis CKD Patients Reference: Haas MH. The risk of death in patients with a high coronary.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
The balANZ Trial. Source Johnson DW, Clarke M, Wilson V, et al. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral.
Risk Involved with Dual RAAS Blockade in Kidney Disease Source: Bakris GL. Dual RAAS blockade is desirable in kidney disease: Con. Kidney Int. 2010;78:546–549.
The RAVE Study Renal Athersosclerotic Revascularization Evaluation Reference Tobe SW, Atri M, Perkins N, et al. Renal Athersosclerotic revascularization.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.
Hemodiafiltration: Clinical Evidence of Higher Benefit Reference: Blankestijn PJ, LedeboI, Canaud B. Hemodiafiltration: Clinical evidence and remaining.
Am J Kidney Dis. 2014;63(6): R3 박세정 /prof. 이태원 Comparative Effectiveness of Early Versus Conventional Timing of Dialysis Initiation in Advanced.
The FRET Study Source: Inoue T, Ikeda H, Nakamura T, et al. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin.
The STAR Study. Cardiovascular Disease Antihypertensives The STAR Study Stent Placement in Patients with Atherosclerotic Renal Artery Stenosis and Impaired.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
The FRACTURE Study (Ongoing). Source West SL, Lok CE, Jamal SA. Fracture Risk Assessment in Chronic Kidney Disease, Prospective Testing Under Real World.
The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.
Renal Replacement Therapy for Prevention of Contrast- induced Acute Kidney Injury: A Meta-analysis of Randomized Controlled Trials Source Song K, Jiang.
Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC
From: Benefits and Harms of Statin Therapy for Persons With Chronic Kidney DiseaseA Systematic Review and Meta-analysis Ann Intern Med. 2012;157(4):
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
The ALERT Trial.
The MASS-DAC Study.
The HEMO Study Hemodialysis (HEMO) Study Reference
The ADEMEX Trial Adequacy of PD in Mexico Reference
CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.
The EuLITE (Ongoing) Source
The EuLITE (Ongoing).
The ECHO Observational Study
The IDEAL Study Reference
Advancing Management of Anemia With the Latest Data From ERA-EDTA 2018
Systolic Blood Pressure Intervention Trial (SPRINT)
Management of perioperative hypertension
SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)
AMACING Trial design: Patients with chronic kidney disease undergoing intravascular iodinated contrast administration were randomized to prophylactic hydration.
Dialysis limitations. Dialysis limitations. (A) Recent data from observational studies and randomized, clinical trials indicate significant limitations.
Presentation transcript:

The DVD Trial

Source Reinecke H, Fobker M, Wellmann J, et al. A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for prevention of contrast medium-induced nephropathy: the Dialysis- versus-Diuresis (DVD) trial. Clin Res Cardiol. 2007;96(3):130–139.

Background There has been an increase in the frequency of contrast-medium-induced nephropathy (CIN) as the number of patients with pre-existing chronic kidney disease (CKD) who are exposed to contrast medium has rapidly increased. CIN has profound consequences on prognosis as it increases the modality by up to a 20-fold during in-hospital stay. Various modalities have been used including hemodialysis to address CIN. Previous analyses of surrogate parameters have suggested beneficial effects of hemodialysis.

Aim To test the hypothesis that a combined treatment of hydration plus hemodialysis, or hydration plus N-acetylcysteine (N-ACC) would be superior to hydration only in preventing CIN.

Methods

Key results There were no significant differences in CIN within 24 h between the three treatment groups. But within 72 h, CIN occurred markedly more often in patients of the hemodialysis group (p=0.008). The frequency of CIN from 48 to 72 h after catheterization was 6.1% in the hydration-only group, 15.9% with hemodialysis treatment, and 5.3% in the N-ACC group. There were no differences between the treatment groups with regard to increased serum creatinine concentrations after 30–60 days (4.8%, 5.1%, and 3.1%, respectively for hydration-only group, hydration plus hemodialysis group, and hydration plus N-ACC group; p=0.700). Analyses of long-term follow-up (range 63–1316 days) by Cox regressions models of the study groups found quite similar survival rates (p=0.500). Patients who still had elevated creatinine concentrations at 30–60 days suffered from a markedly higher 2-year mortality (46% vs 17%, p=0.002).

Conclusion Hemodialysis in addition to hydration therapy does not provide any outcome benefit in prevention of CIN; on the contrary this study provides evidence that this combination would harm the patient. Also, as observed, increased creatinine concentrations at 30–60 days, but not within 72 h, were associated with markedly reduced long-term survival. Hemodialysis when coupled with hydration therapy is associated with significant decrements in long-term survival.